Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.78 Insider Own0.40% Shs Outstand218.63M Perf Week-6.97%
Market Cap24.24B Forward P/E250.79 EPS next Y0.44 Insider Trans-13.84% Shs Float209.64M Perf Month-10.35%
Income-153.80M PEG- EPS next Q0.04 Inst Own93.50% Short Float1.85% Perf Quarter-18.66%
Sales1.31B P/S18.55 EPS this Y-251.90% Inst Trans-1.34% Short Ratio2.90 Perf Half Y-20.62%
Book/sh5.01 P/B22.13 EPS next Y153.70% ROA-9.60% Target Price147.50 Perf Year24.17%
Cash/sh2.78 P/C39.81 EPS next 5Y- ROE-22.10% 52W Range83.01 - 153.15 Perf YTD10.55%
Dividend- P/FCF496.62 EPS past 5Y18.70% ROI13.20% 52W High-27.62% Beta0.93
Dividend %- Quick Ratio2.90 Sales past 5Y63.60% Gross Margin94.30% 52W Low33.54% ATR4.41
Employees980 Current Ratio2.90 Sales Q/Q32.50% Oper. Margin-4.70% RSI (14)26.49 Volatility3.20% 3.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-134.10% Profit Margin-11.80% Rel Volume1.62 Prev Close115.05
ShortableYes LT Debt/Eq0.02 EarningsOct 31 BMO Payout- Avg Volume1.34M Price110.85
Recom2.00 SMA20-11.98% SMA50-13.31% SMA200-11.49% Volume2,174,075 Change-3.65%
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-10-17Initiated Gabelli & Co Buy $185
Apr-07-17Reiterated Barclays Overweight $135 → $185
Apr-05-17Downgrade Raymond James Outperform → Mkt Perform
Apr-04-17Reiterated RBC Capital Mkts Outperform $138 → $157
Mar-09-17Initiated UBS Neutral $140
Mar-02-17Initiated Instinet Buy $148
Feb-15-17Reiterated RBC Capital Mkts Outperform $123 → $138
Jan-23-17Initiated Credit Suisse Outperform
Oct-12-16Reiterated RBC Capital Mkts Outperform $106 → $113
Sep-29-16Upgrade Raymond James Mkt Perform → Outperform
Aug-10-16Reiterated Leerink Partners Outperform $85 → $95
Aug-10-16Reiterated Barclays Overweight $85 → $100
Aug-05-16Initiated SunTrust Buy
Jul-13-16Initiated RBC Capital Mkts Outperform $105
Mar-30-16Reiterated Leerink Partners Outperform $94 → $85
Sep-24-17 09:09AM  3 Monster Biotech Stocks in the Making Motley Fool
Sep-21-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-20-17 08:01AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Sep-19-17 04:05PM  Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress GlobeNewswire
Sep-18-17 10:00AM  Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Sep-15-17 09:51AM  Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study Zacks
Sep-14-17 02:49PM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
01:19PM  Have Investors Already Priced In Incyte Corporations (INCY) Growth? Simply Wall St.
11:35AM  Lilly/Incyte pill beats placebo in mid-stage eczema trial Reuters
09:00AM  Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-13-17 06:39PM  ETFs with exposure to Incyte Corp. : September 13, 2017 Capital Cube
Sep-12-17 09:28AM  This Analyst Predicts Bullish Growth Outlook For Incyte Benzinga
Sep-11-17 02:30PM  Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
10:44AM  Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017 Capital Cube
10:21AM  [$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances Financial Times
Sep-09-17 08:49AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
08:45AM  Progression-Free Survival Data from ECHO-202 Trial of Incytes Epacadostat in Combination with Mercks KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma Business Wire
Sep-08-17 10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com
08:35AM  Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock Business Wire
Sep-07-17 05:28PM  Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock Business Wire
Sep-05-17 11:50AM  Alexion: Quite a Comeback Barrons.com
10:46AM  The Key Reason Incyte Corporation Added $850 Million in Market Cap in August Motley Fool
Sep-01-17 05:32PM  Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda Zacks
05:04PM  Top Research Reports for Bank of America, Pepsi & American Express Zacks
09:00AM  Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month Business Wire
Aug-31-17 01:39PM  Why $475,000 isn't actually that expensive for Novartis's new drug Yahoo Finance
11:10AM  Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected Zacks
09:08AM  Incyte and Gilead Sciences: S&P 500s Top Gainers on August 30 Market Realist
08:55AM  Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : August 31, 2017 Capital Cube
08:42AM  Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update Zacks
08:00AM  Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation ACCESSWIRE
Aug-30-17 07:05PM  New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma Business Wire +10.64%
04:58PM  The Hot Stocks: Incyte Jumps 11% Barrons.com
04:43PM  What Analysts Recommend for United Therapeutics in August 2017 Market Realist
03:23PM  Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval MarketWatch
09:46AM  Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers TheStreet.com
06:45AM  Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 PR Newswire
Aug-29-17 03:26PM  2 Stocks Fall on Earnings Report GuruFocus.com
08:05AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
03:00AM  IBD Rating Upgrades: Incyte Shows Improved Price Strength Investor's Business Daily
Aug-28-17 08:05AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Aug-24-17 10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
Aug-23-17 11:53AM  Incyte Had These Key Collaborations and Developments in 2Q17 Market Realist
09:07AM  Inside Incytes Jakafi Performance in 2Q17 Market Realist
07:37AM  Behind Incytes 2Q17 Product Portfolio Market Realist
Aug-22-17 02:05PM  Understanding Incytes 2Q17 Revenue Stream Market Realist
12:35PM  Assessing Incytes 2Q17 Revenue Growth Market Realist
10:56AM  Inside Incytes Valuation after the 2Q17 Earnings Market Realist
07:23AM  3 Most Promising Cancer Drugs in Late-Stage Development Motley Fool
Aug-17-17 08:04AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Aug-16-17 08:02AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Aug-15-17 05:57PM  Incyte Corp. Value Analysis (NASDAQ:INCY) : August 15, 2017 Capital Cube
04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Aug-13-17 03:36AM  Edited Transcript of INCY earnings conference call or presentation 1-Aug-17 2:00pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Aug-10-17 08:45AM  Forbes Magazine Names Incyte One of the Worlds Most Innovative Companies for Third Consecutive Year Business Wire -6.12%
08:04AM  IHS Markit Score Update: Drop in demand for ETFs holding Incyte Corp is a negative sign for its shares Markit
Aug-02-17 11:05AM  Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong Zacks
09:19AM  Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : August 2, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Incyte Corporation ACCESSWIRE
Aug-01-17 10:56PM  Incyte reports 2Q loss Associated Press
11:41AM  Incyte Corporation (INCY) Shares Drop on Q2 Loss InvestorPlace
08:00AM  Investor Network: Incyte Corporation to Host Earnings Call ACCESSWIRE
07:00AM  Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs Business Wire
Jul-31-17 10:30AM  Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY Zacks
Jul-26-17 08:15AM  Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug Zacks
06:00AM  Gilead Faces 6th Quarter of Falling Revenue Investopedia
Jul-25-17 04:17PM  Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug TheStreet.com
04:02PM  Eli Lilly Tumbles On Arthritis Drug Delay Investor's Business Daily
12:10PM  Eli Lilly: What the Heck Just Happened? Barrons.com
06:58AM  Eli Lilly beats profit and sales expectations; NDA for RA treatment to be delayed MarketWatch
06:15AM  Lilly and Incyte Provide Update on Baricitinib PR Newswire
Jul-21-17 02:42PM  2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't Motley Fool
Jul-20-17 07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease Business Wire
Jul-18-17 06:00AM  Why Gilead Won't Buy Incyte and Vertex Investopedia
Jul-14-17 04:44PM  Gilead Could Acquire This Biotech But Vertex Is Still Better: Analyst Investor's Business Daily
02:37PM  Could Q2 Surprise Spike This Beleaguered Biotech's Stock? Investor's Business Daily
Jul-11-17 04:06PM  Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results GlobeNewswire
08:00AM  Incyte to Report Second Quarter Financial Results Business Wire
Jul-04-17 10:37AM  What Analysts Recommend for United Therapeutics in June 2017 Market Realist
07:53AM  Incyte & Lilly's Olumiant Gets Marketing Approval in Japan Zacks
07:36AM  Keytrudas Developments in June 2017 Market Realist
Jul-03-17 08:00AM  Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis PR Newswire
Jun-30-17 04:13PM  Gilead And Vertex Should Join But Don't Hold Your Breath: Analyst Investor's Business Daily
03:04PM  ETFs with exposure to Incyte Corp. : June 30, 2017 Capital Cube
Jun-29-17 09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca Zacks
Jun-27-17 12:44PM  Edited Transcript of INCY earnings conference call or presentation 4-May-17 2:00pm GMT Thomson Reuters StreetEvents
Jun-26-17 02:52PM  Seattle Genetics: A Disappointing StudyOr Was It? Barrons.com
06:00AM  The Reason for the Big Rise in Biotech Stocks Investopedia
Jun-22-17 08:15AM  Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : June 22, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Amgen and Incyte Accesswire
Jun-21-17 12:42PM  4 Stocks & ETFs to Buy on Clovis' Positive Drug Data Zacks +7.55%
09:35AM  Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More Zacks
Jun-20-17 02:39PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
Jun-19-17 05:37PM  Three must-own cancer stocks for your biotechnology portfolio MarketWatch
03:32PM  ETFs with exposure to Incyte Corp. : June 19, 2017 Capital Cube
08:00AM  A Surprising Disappointment Derails NewLink Genetics -- What's Next? Motley Fool
Jun-17-17 06:42AM  3 Biotech Stocks That Could Become M&A Targets Motley Fool
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoppenot HerveChairman / CEOSep 18Sale119.4570,5028,421,464299,004Sep 20 04:28 PM
Flannelly Barry PEVP & General Manager USSep 14Sale124.2571488,71514,782Sep 15 04:11 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy132.00100,00013,200,00029,247,347Sep 08 05:06 PM
Trower PaulPrincipal Accounting OfficerSep 05Option Exercise17.793,00053,37014,853Sep 07 04:04 PM
Trower PaulPrincipal Accounting OfficerSep 05Sale138.413,000415,23011,853Sep 07 04:04 PM
Siegel Eric H.EVP, General CounselSep 01Option Exercise64.551,820117,48123,553Sep 05 04:27 PM
Siegel Eric H.EVP, General CounselSep 01Sale137.401,820250,06821,733Sep 05 04:27 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Option Exercise17.7920,000355,80055,067Sep 05 04:22 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Sale140.0020,0002,800,00035,067Sep 05 04:22 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Option Exercise89.522,111188,97420,276Aug 31 04:13 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Sale125.002,111263,87518,165Aug 31 04:13 PM
Trower PaulPrincipal Accounting OfficerAug 04Option Exercise17.793,00053,37014,853Aug 07 04:33 PM
Trower PaulPrincipal Accounting OfficerAug 04Sale125.253,000375,75011,853Aug 07 04:33 PM
Siegel Eric H.EVP, General CounselAug 01Option Exercise64.551,820117,48123,553Aug 03 04:54 PM
Siegel Eric H.EVP, General CounselAug 01Sale132.921,820241,91421,733Aug 03 04:54 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Option Exercise85.686,485555,64124,650Jul 21 04:01 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Sale131.096,485850,11918,165Jul 21 04:01 PM
Trower PaulPrincipal Accounting OfficerJul 05Option Exercise17.793,00053,37015,148Jul 07 05:02 PM
Trower PaulPrincipal Accounting OfficerJul 05Sale126.183,000378,54012,148Jul 07 05:02 PM
Siegel Eric H.EVP, General CounselJul 03Option Exercise64.551,820117,48120,036Jul 05 06:20 PM
Siegel Eric H.EVP, General CounselJul 03Sale126.201,820229,68418,216Jul 05 06:20 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Option Exercise73.2159943,85319,614Jul 05 04:12 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Sale129.7459977,71419,015Jul 05 04:12 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Option Exercise91.459,883903,82424,531Jun 22 04:29 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Sale125.009,8831,235,37514,648Jun 22 04:29 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Option Exercise73.2116,7561,226,70735,771Jun 14 04:50 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Sale116.6016,7561,953,75019,015Jun 14 04:50 PM
Siegel Eric H.EVP, General CounselJun 06Option Exercise66.661,29286,12718,216Jun 07 04:21 PM
Trower PaulPrincipal Accounting OfficerJun 05Option Exercise17.793,00053,37013,950Jun 07 04:12 PM
Trower PaulPrincipal Accounting OfficerJun 05Sale132.503,000397,50010,950Jun 07 04:12 PM
Siegel Eric H.EVP, General CounselJun 01Option Exercise64.551,820117,48118,744Jun 02 04:22 PM
Siegel Eric H.EVP, General CounselJun 01Sale130.001,820236,60016,924Jun 02 04:22 PM
BIENAIME JEAN JACQUESDirectorMay 31Buy131.8050065,9004,677Jun 02 04:14 PM
BIENAIME JEAN JACQUESDirectorMay 15Buy115.0050057,5004,177May 17 04:18 PM
Huber Reid MEVP, Chief Scientific OfficerMay 08Sale119.218,5771,022,46436,037May 09 04:38 PM
Trower PaulPrincipal Accounting OfficerMay 05Option Exercise17.793,00053,37013,950May 09 04:17 PM
Trower PaulPrincipal Accounting OfficerMay 05Sale121.703,000365,10010,950May 09 04:17 PM
Siegel Eric H.EVP, General CounselMay 01Option Exercise64.551,820117,48118,744May 02 05:52 PM
Flannelly Barry PEVP & General Manager USMay 01Option Exercise48.442,06499,98017,949May 02 06:01 PM
Siegel Eric H.EVP, General CounselMay 01Sale124.731,820227,00916,924May 02 05:52 PM
Flannelly Barry PEVP & General Manager USMay 01Sale124.735,296660,56412,653May 02 06:01 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Option Exercise67.061,38993,14620,404May 02 05:39 PM
BIENAIME JEAN JACQUESDirectorApr 28Buy124.2650062,1303,677May 02 04:31 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Sale124.261,389172,59719,015May 02 05:39 PM
BAKER BROS. ADVISORS LPDirectorApr 27Option Exercise7.2660,000435,60029,161,795Apr 28 05:10 PM
BIENAIME JEAN JACQUESDirectorApr 13Buy139.661,000139,6603,177Apr 17 04:56 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Option Exercise67.0641,5282,784,86860,543Apr 11 04:14 PM
Siegel Eric H.EVP, General CounselApr 10Option Exercise39.134,043158,20620,828Apr 11 04:19 PM
Siegel Eric H.EVP, General CounselApr 10Sale140.184,043566,74816,785Apr 11 04:19 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Sale138.0041,5285,730,86419,015Apr 11 04:14 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Option Exercise89.7932,0002,873,16046,648Apr 11 04:24 PM
BIENAIME JEAN JACQUESDirectorApr 07Buy139.481,000139,4802,177Apr 11 04:06 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Sale137.8832,0004,412,31014,648Apr 11 04:24 PM
FRIEDMAN PAUL ADirectorMar 17Option Exercise18.3241,693763,816339,211Mar 20 04:10 PM
BROOKE PAUL ADirectorMar 17Option Exercise7.2620,000145,200216,756Mar 20 04:14 PM
BROOKE PAUL ADirectorMar 17Sale147.7520,0002,955,000196,756Mar 20 04:14 PM
FRIEDMAN PAUL ADirectorMar 17Sale148.1841,6936,178,069297,518Mar 20 04:10 PM
FRIEDMAN PAUL ADirectorMar 16Option Exercise18.328,307152,184305,825Mar 20 04:10 PM
FRIEDMAN PAUL ADirectorMar 16Sale151.458,3071,258,095297,518Mar 20 04:10 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 27Sale131.882,008264,81552,262Mar 01 04:56 PM
FRIEDMAN PAUL ADirectorFeb 23Option Exercise18.3250,000916,000347,518Feb 27 04:54 PM
FRIEDMAN PAUL ADirectorFeb 23Sale120.3250,0006,016,000297,518Feb 27 04:54 PM
Huber Reid MEVP, Chief Scientific OfficerJan 09Sale113.5511,7391,332,96352,185Jan 11 04:21 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Option Exercise14.7210,000147,20039,248Nov 17 04:29 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Sale103.2610,0001,032,60029,248Nov 17 04:29 PM
Huber Reid MEVP, Chief Scientific OfficerNov 09Sale109.952,715298,51463,924Nov 10 04:34 PM
SWAIN PAULA JEVP, Human ResourcesOct 20Option Exercise14.7210,000147,20039,248Oct 24 04:44 PM
SWAIN PAULA JEVP, Human ResourcesOct 20Sale90.0010,000900,00029,248Oct 24 04:44 PM
Flannelly Barry PEVP & General Manager USOct 07Option Exercise48.4424,2041,172,44235,391Oct 11 04:33 PM
Huber Reid MEVP, Chief Scientific OfficerOct 07Option Exercise18.3211,709214,50978,310Oct 11 04:37 PM
Huber Reid MEVP, Chief Scientific OfficerOct 07Sale96.4011,7091,128,74866,601Oct 11 04:37 PM
Flannelly Barry PEVP & General Manager USOct 07Sale97.0024,2042,347,78811,187Oct 11 04:33 PM